FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII

November 15, 2017 -- The U.S. Food and Drug Administration today approved Mepsevii (vestronidase alfa-vjbk) to treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news